As antibody-drug conjugates become more sophisticated, understanding their behavior requires more than a single analytical perspective. DAR characterization, multi-analyte PK, immunogenicity assessment and intact mass spectrometry are becoming increasingly important for teams working to generate robust development insight from complex ADC candidates.

On 22 April 2026 at 2:00 PM CET, Quinta-Analytica, a Conscio Group company, invites you to join a focused expert webinar organised together with SigutLabs:

ADC Performance by Design: From Linker Chemistry to DAR and Bioanalytical Insight

The session will connect upstream chemistry decisions with downstream analytical and bioanalytical interpretation. Topics will include linker design, conjugation strategy, DAR control, conjugate stability, multi-analyte PK, immunogenicity and high-resolution mass spectrometry for intact ADC analysis.

Program highlights:

  • The Organic Chemist’s Role in Enhancing ADC Performance
    Speaker: Alessandro Panattoni, Head of Chemistry, SigutLabs
  • Navigating the Complexity of ADCs: Integrated Analytical and Bioanalytical Strategies for Next-Generation Biotherapeutics
    Speaker: Milan Maděra, Head of Biologics Department, Conscio Group
  • Opening remarks & ADC market insights
    Host: Jiří Raška, CCO, Conscio Group/Quinta-Analytica

Whether you work in bioanalysis, analytical development, CMC or cross-functional ADC programs, this webinar will offer practical insight into the decisions that influence candidate quality, development readiness and translational understanding. The session includes a live Q&A, giving participants the opportunity to engage directly with the speakers.

Register here to secure your spot. Participation is free.

Additional News

  • 15 July 2026

    Quinta-Analytica Awarded the EcoVadis Gold Medal

    Quinta-Analytica has been awarded the EcoVadis Gold Medal after achieving an overall sustainability score of 84 out of 100. The result represents a substantial increase from 68 points in the previous assessment and places the company in the 97th percentile globally.

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.